Jade Biosciences is burning through $30.8 million per quarter in R&D and moving faster than it expected. The company said Thursday that its EVERGREEN Phase 3 registrational trial of JADE101 in IgA nephropathy will start in Q4 2026, ahead of its prior schedule, with the Phase 1 JADE301 program in dermatomyositis also set to enter the clinic this quarter. With $475.7 million in cash as of September 30, Jade says it has runway into Q4 2028, buying enough time to reach several data readouts before it needs to raise again.
The pace matters because the IgA nephropathy field has grown crowded fast: budesonide-based therapies and additional agents have entered the IgAN space in recent years, and additional agents have followed. JADE101 targets APRIL, a cytokine implicated in IgAN-related kidney damage. The parallel Phase 2 JUNIPER trial remains enrolling, with interim data expected in Q2 2027. Running both trials simultaneously will contribute to ongoing R&D spending through 2027.
JADE301, the anti-IFN-β antibody for dermatomyositis, generated the most eye-catching preclinical number in this update: a roughly 25-day half-life after subcutaneous dosing in non-human primates. That figure, if it holds in humans, could support monthly or less frequent dosing, which matters for a rare disease where patient burden affects adherence and trial retention alike. Preclinical comparisons to dazukibart showed greater functional potency in disease-relevant human cells, though that head-to-head framing will need clinical data to carry any weight. Interim results from the healthy volunteer Phase 1 are expected in the second half of 2027.
R&D spending rose $8.8 million year-over-year to $30.8 million in Q3, with manufacturing, clinical activity, and personnel-related costs driving the increase, and G&A added another $3.4 million increase on the prior year. The net loss of $35.1 million for the quarter reflects a company accelerating on multiple fronts simultaneously. The number to watch from here is not cash burn in isolation, but whether JUNIPER interim data in Q2 2027 supports continued confidence in the EVERGREEN design.
Source link: https://www.sec.gov/Archives/edgar/data/1798749/000119312526459287/d157312d8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
